CRISPR THERAPEUTICS AG Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
CRISPR THERAPEUTICS AG (CRSP) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$2.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-03
- CRISPR THERAPEUTICS AG other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$2.69M.
- CRISPR THERAPEUTICS AG other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$6.76M, a 394.64% decline year-over-year.
- CRISPR THERAPEUTICS AG other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $945.00K, a 92.97% decline year-over-year.
- CRISPR THERAPEUTICS AG other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was -$94.00K.
- CRISPR THERAPEUTICS AG other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$2.98M.
- CRISPR THERAPEUTICS AG other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$73.00K, a 100.42% decline from fiscal 2023.
- CRISPR THERAPEUTICS AG other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $17.56M.
- CRISPR THERAPEUTICS AG other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$10.58M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.69M 10-Q · filed 2026-08-03 | -$9.45M derived: sum of 2 quarters · filed 2026-08-03 | ||
| 2026-03-31 | -$6.76M 10-Q · filed 2026-08-03 | |||
| 2025-12-31 | -$2.98M 10-K · filed 2026-02-12 | |||
| 2025-09-30 | $945.00K 10-Q · filed 2025-11-10 | $851.00K derived: sum of 2 quarters · filed 2026-08-03 | $3.15M derived: sum of 3 quarters · filed 2026-08-03 | |
| 2025-06-30 | -$94.00K 10-Q · filed 2026-08-03 | $2.20M derived: sum of 2 quarters · filed 2026-08-03 | ||
| 2025-03-31 | $2.29M 10-Q · filed 2026-08-03 | |||
| 2024-12-31 | -$73.00K 10-K · filed 2026-02-12 | |||
| 2024-09-30 | $13.44M 10-Q · filed 2025-11-10 | $12.12M derived: sum of 2 quarters · filed 2025-11-10 | $8.65M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | -$1.33M 10-Q · filed 2025-11-10 | -$4.79M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | -$3.46M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $17.56M 10-K · filed 2026-02-12 | |||
| 2023-09-30 | $2.11M 10-Q · filed 2024-11-05 | $2.59M derived: sum of 2 quarters · filed 2024-11-05 | $8.85M derived: sum of 3 quarters · filed 2024-11-05 | |
| 2023-06-30 | $480.00K 10-Q · filed 2024-11-05 | $6.74M derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2023-03-31 | $6.26M 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | -$10.58M 10-K · filed 2025-02-11 | |||
| 2022-09-30 | -$1.92M 10-Q · filed 2023-11-06 | -$5.37M derived: sum of 2 quarters · filed 2023-11-06 | -$17.20M derived: sum of 3 quarters · filed 2023-11-06 | |
| 2022-06-30 | -$3.45M 10-Q · filed 2023-11-06 | -$15.28M derived: sum of 2 quarters · filed 2023-11-06 | ||
| 2022-03-31 | -$11.83M 10-Q · filed 2023-11-06 | |||
| 2021-12-31 | -$4.98M 10-K · filed 2024-02-21 | |||
| 2021-09-30 | -$141.00K 10-Q · filed 2022-11-01 | -$309.00K derived: sum of 2 quarters · filed 2022-11-01 | -$687.00K derived: sum of 3 quarters · filed 2022-11-01 | |
| 2021-06-30 | -$168.00K 10-Q · filed 2022-11-01 | -$546.00K derived: sum of 2 quarters · filed 2022-11-01 | ||
| 2021-03-31 | -$378.00K 10-Q · filed 2022-11-01 | |||
| 2020-12-31 | -$90.00K 10-K · filed 2023-02-21 | |||
| 2020-09-30 | -$113.00K 10-Q · filed 2021-11-03 | -$116.00K derived: sum of 2 quarters · filed 2021-11-03 | -$141.00K derived: sum of 3 quarters · filed 2021-11-03 | |
| 2020-06-30 | -$3.00K 10-Q · filed 2021-11-03 | -$28.00K derived: sum of 2 quarters · filed 2021-11-03 | ||
| 2020-03-31 | -$25.00K 10-Q · filed 2021-11-03 | |||
| 2019-12-31 | $15.00K 10-K · filed 2022-02-15 | |||
| 2019-09-30 | -$12.00K 10-Q · filed 2020-10-28 | -$22.00K derived: sum of 2 quarters · filed 2020-10-28 | -$14.00K derived: sum of 3 quarters · filed 2020-10-28 | |
| 2019-06-30 | -$10.00K 10-Q · filed 2020-10-28 | -$2.00K derived: sum of 2 quarters · filed 2020-10-28 | ||
| 2019-03-31 | $8.00K 10-Q · filed 2020-10-28 | |||
| 2018-12-31 | -$22.00K 10-K · filed 2021-02-16 | |||
| 2018-09-30 | -$6.00K 10-Q · filed 2019-10-28 | -$27.00K derived: sum of 2 quarters · filed 2019-10-28 | -$15.00K derived: sum of 3 quarters · filed 2019-10-28 | |
| 2018-06-30 | -$21.00K 10-Q · filed 2019-10-28 | -$9.00K derived: sum of 2 quarters · filed 2019-10-28 | ||
| 2018-03-31 | $12.00K 10-Q · filed 2019-10-28 | |||
| 2017-12-31 | $40.00K 10-K · filed 2020-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |